Skip to main
XOMA

XOMA (XOMA) Stock Forecast & Price Target

XOMA (XOMA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

XOMA Royalty Corp is positioned for substantial growth, with projected revenue increases exceeding 20% annually through 2026, driven primarily by commercial sales ramp-ups of key products and new launches. The company reported a significant rise in total income—$28.5 million in 2024 compared to $4.8 million in 2023—attributed to enhancements in purchased receivables and customer contracts. Furthermore, forecasts for 2026 anticipate revenues reaching $49.0 million, reflecting a 36% increase from the preceding year, bolstered by both commercial-stage assets and potential milestone payments from earlier-stage assets.

Bears say

XOMA Royalty Corp has experienced significant variability in its revenues and net earnings, primarily due to the volatility associated with the international markets for its products, which could lead to adverse impacts on operations amid potential global economic downturns, tariffs, or changes in reimbursement policies. The company's reliance on partnerships and future economic rights from pre-commercial therapeutic candidates may expose it to risks such as failed clinical trials or challenges in securing necessary funding, which could impede its ability to progress drug development. Furthermore, recent declines in share performance following a pandemic-related peak and concerns regarding potential executive departures could amplify operational challenges and negatively affect investor confidence.

XOMA (XOMA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About XOMA (XOMA) Forecast

Analysts have given XOMA (XOMA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, XOMA (XOMA) has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

XOMA (XOMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.